BD PharmingenTM FITC Rat Anti-Human IL-2

Description

Flow cytometric analysis of IL-2 expression by stimulated CD3+ human PBMC. Human PBMC were stimulated for 6 hours with PMA Sigma, Cat. #P-8139 and calcium ionophore A23187 Sigma, Cat. #C-9275 in the presence of 2 muM GolgiStop Cat. No. 554724 . The PBMCs were stained with PE-Cy5 Mouse Anti-Human CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with FITC Rat Anti-Human IL-2 0.25 mug; Cat. No. 554565/561055/559361; left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with a molar excess of recombinant human IL-2 protein 1.0 mug, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of the Purified Rat Anti-Human IL-2 10 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the blocking controls. Flow cytometric analysis of IL-2 expression by stimulated CD3+ human PBMC. Human PBMC were stimulated for 6 hours with PMA Sigma, Cat. #P-8139 and calcium ionophore A23187 Sigma, Cat. #C-9275 in the presence of 2 muM GolgiStop Cat. No. 554724 . The PBMCs were stained with PE-Cy5 Mouse Anti-Human CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with FITC Rat Anti-Human IL-2 0.25 mug; Cat. No. 554565/561055/559361; left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with a molar excess of recombinant human IL-2 protein 1.0 mug, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of the Purified Rat Anti-Human IL-2 10 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the blocking controls. Flow cytometric analysis of IL-2 expression by stimulated CD3+ human PBMC. Human PBMC were stimulated for 6 hours with PMA Sigma, Cat. #P-8139 and calcium ionophore A23187 Sigma, Cat. #C-9275 in the presence of 2 muM GolgiStop Cat. No. 554724 . The PBMCs were stained with PE-Cy5 Mouse Anti-Human CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with FITC Rat Anti-Human IL-2 0.25 mug; Cat. No. 554565/561055/559361; left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with a molar excess of recombinant human IL-2 protein 1.0 mug, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of the Purified Rat Anti-Human IL-2 10 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the blocking controls. Show More Flow cytometric analysis of IL-2 expression by stimulated CD3+ human PBMC. Human PBMC were stimulated for 6 hours with PMA Sigma, Cat. #P-8139 and calcium ionophore A23187 Sigma, Cat. #C-9275 in the presence of 2 muM GolgiStop Cat. No. 554724 . The PBMCs were stained with PE-Cy5 Mouse Anti-Human CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with FITC Rat Anti-Human IL-2 0.25 mug; Cat. No. 554565/561055/559361; left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with a molar excess of recombinant human IL-2 protein 1.0 mug, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of the Purified Rat Anti-Human IL-2 10 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the blocking controls. Show More Flow cytometric analysis of IL-2 expression by stimulated CD3+ human PBMC. Human PBMC were stimulated for 6 hours with PMA Sigma, Cat. #P-8139 and calcium ionophore A23187 Sigma, Cat. #C-9275 in the presence of 2 muM GolgiStop Cat. No. 554724 . The PBMCs were stained with PE-Cy5 Mouse Anti-Human CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with FITC Rat Anti-Human IL-2 0.25 mug; Cat. No. 554565/561055/559361; left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with a molar excess of recombinant human IL-2 protein 1.0 mug, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of the Purified Rat Anti-Human IL-2 10 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the blocking controls. Flow cytometric analysis of IL-2 expression by stimulated CD3+ human PBMC. Human PBMC were stimulated for 6 hours with PMA Sigma, Cat. #P-8139 and calcium ionophore A23187 Sigma, Cat. #C-9275 in the presence of 2 muM GolgiStop Cat. No. 554724 . The PBMCs were stained with PE-Cy5 Mouse Anti-Human CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with FITC Rat Anti-Human IL-2 0.25 mug; Cat. No. 554565/561055/559361; left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with a molar excess of recombinant human IL-2 protein 1.0 mug, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of the Purified Rat Anti-Human IL-2 10 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the blocking controls.